Centre d'Information et de documentation du CRA Rhône-Alpes
CRA
Informations pratiques
-
Adresse
Centre d'information et de documentation
du CRA Rhône-Alpes
Centre Hospitalier le Vinatier
bât 211
95, Bd Pinel
69678 Bron CedexHoraires
Lundi au Vendredi
9h00-12h00 13h30-16h00Contact
Tél: +33(0)4 37 91 54 65
Mail
Fax: +33(0)4 37 91 54 37
-
Détail de l'auteur
Auteur Osamu YOTSUYA |
Documents disponibles écrits par cet auteur (1)
Faire une suggestion Affiner la recherche
Melatonin Treatment and Adequate Sleep Hygiene Interventions in Children with Autism Spectrum Disorder: A Randomized Controlled Trial / Masaharu HAYASHI in Journal of Autism and Developmental Disorders, 52-6 (June 2022)
[article]
Titre : Melatonin Treatment and Adequate Sleep Hygiene Interventions in Children with Autism Spectrum Disorder: A Randomized Controlled Trial Type de document : Texte imprimé et/ou numérique Auteurs : Masaharu HAYASHI, Auteur ; Kazuo MISHIMA, Auteur ; Michio FUKUMIZU, Auteur ; Hiroyuki TAKAHASHI, Auteur ; Yuko ISHIKAWA, Auteur ; Izumi HAMADA, Auteur ; Hideyuki SUGIOKA, Auteur ; Osamu YOTSUYA, Auteur ; Yushiro YAMASHITA, Auteur Article en page(s) : p.2784-2793 Langues : Anglais (eng) Mots-clés : Autism spectrum disorder Melatonin Randomized controlled trial Sleep hygiene interventions Sleep problems Index. décimale : PER Périodiques Résumé : Robust clinical evidence has not been available for melatonin, a drug commonly administered for treating sleep problems of children with autism spectrum disorder (ASD). In a phase 3 randomized, placebo-controlled clinical trial, we administered 1-mg melatonin (n=65), 4-mg melatonin (n=65), or placebo (n=66) to196 children with ASD once daily before bedtime under adequate sleep hygiene interventions. The primary outcome was sleep onset latency (SOL) assessed with the electronic sleep diary. SOL shortened significantly in the 1- and 4-mg melatonin groups compared to the placebo group (- 22.0, - 28.0, and - 5.0 min, respectively; p?0.0001 each). This therapeutic regimen of melatonin is a reasonable clinical approach to cope with ASD-emergent difficulties in children with ASD. En ligne : http://dx.doi.org/10.1007/s10803-021-05139-w Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=474
in Journal of Autism and Developmental Disorders > 52-6 (June 2022) . - p.2784-2793[article] Melatonin Treatment and Adequate Sleep Hygiene Interventions in Children with Autism Spectrum Disorder: A Randomized Controlled Trial [Texte imprimé et/ou numérique] / Masaharu HAYASHI, Auteur ; Kazuo MISHIMA, Auteur ; Michio FUKUMIZU, Auteur ; Hiroyuki TAKAHASHI, Auteur ; Yuko ISHIKAWA, Auteur ; Izumi HAMADA, Auteur ; Hideyuki SUGIOKA, Auteur ; Osamu YOTSUYA, Auteur ; Yushiro YAMASHITA, Auteur . - p.2784-2793.
Langues : Anglais (eng)
in Journal of Autism and Developmental Disorders > 52-6 (June 2022) . - p.2784-2793
Mots-clés : Autism spectrum disorder Melatonin Randomized controlled trial Sleep hygiene interventions Sleep problems Index. décimale : PER Périodiques Résumé : Robust clinical evidence has not been available for melatonin, a drug commonly administered for treating sleep problems of children with autism spectrum disorder (ASD). In a phase 3 randomized, placebo-controlled clinical trial, we administered 1-mg melatonin (n=65), 4-mg melatonin (n=65), or placebo (n=66) to196 children with ASD once daily before bedtime under adequate sleep hygiene interventions. The primary outcome was sleep onset latency (SOL) assessed with the electronic sleep diary. SOL shortened significantly in the 1- and 4-mg melatonin groups compared to the placebo group (- 22.0, - 28.0, and - 5.0 min, respectively; p?0.0001 each). This therapeutic regimen of melatonin is a reasonable clinical approach to cope with ASD-emergent difficulties in children with ASD. En ligne : http://dx.doi.org/10.1007/s10803-021-05139-w Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=474